Merck (MRK) stock gains as a cancer drug the company develops with Kelun-Biotech bests its Keytruda blockbuster in a ...

Randomized double-blind phase 3 enrolled 1546 treatment-naive unresectable/metastatic melanoma patients, including adolescents, testing two fianlimab doses plus ...

Eli Lilly’s diabetes drug Mounjaro has become the world’s top-selling medication, surpassing Merck’s cancer therapy Keytruda. Lilly’s performance compounded when Mounjaro and weight-loss drug Zepbound ...

Samsung Bioepis Co., Ltd. announced today that the Phase 1 study on SB27, a proposed biosimilar to Keytruda 1 (pembrolizumab), has met its primary pharmacokinetics (PK) endpoints. The randomized, ...

Merck reported higher first-quarter sales and raised its full-year earnings guidance as demand for its flagship Keytruda cancer drug continues to grow. Sales rose 5% to $16.29 billion, boosted by 12% ...

The Food and Drug Administration (FDA) has granted Priority Review to enfortumab vedotin-ejfv (Padcev ™) in combination with pembrolizumab (Keytruda ®) or pembrolizumab and berahyaluronidase alfa-pmph ...

A study published April 10 in The Lancet reports that the anti-PD-1 immunotherapy pembrolizumab (brand name Keytruda) significantly improved overall survival in adults with platinum-resistant ovarian ...

The KEYTRUDA regimen is the first and only PD-1 inhibitor-based treatment approved in the European Union for these patients Approval supported by data from the Phase 3 KEYNOTE-B96 trial in which the ...

Merck (MRK) said that an analysis of a phase 3 trial found that treatment with Keytruda (pembrolizumab) led to a significant improvement in overall survival regardless of an ovarian cancer patient's ...

Synthekine Announces Clinical Trial Collaboration with Merck to Evaluate STK-012 In Combination with Keytruda® (Pembrolizumab) and Chemotherapy in Ongoing Randomized Phase 2 Trial in First-Line, PD-L1 ...